|
1
|
Boscaro M, Barzon L, Fallo F and Sonino N:
Cushing’s syndrome. Lancet. 357:783–791. 2001.
|
|
2
|
Arnaldi G, Angeli A, Atkinson AB, et al:
Diagnosis and complications of Cushing’s syndrome: a consensus
statement. J Clin Endocrinol Metab. 88:5593–5602. 2003.
|
|
3
|
Witek P, Zielinski G, Szamotulska K, Witek
J and Zgliczynski W: Complications of Cushing’s disease -
prospective evaluation and clinical characteristics. Do they affect
the efficacy of surgical treatment? Endokrynol Pol. 63:277–285.
2012.
|
|
4
|
Swearingen B: Update on pituitary surgery.
J Clin Endocrinol Metab. 97:1073–1081. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Atkinson AB, Kennedy A, Wiggam MI, McCance
DR and Sheridan B: Long-term remission rates after pituitary
surgery for Cushing’s disease: the need for long-term surveillance.
Clin Endocrinol (Oxf). 63:549–559. 2005.
|
|
6
|
Heaney AP: Clinical review: pituitary
carcinoma: difficult diagnosis and treatment. J Clin Endocrinol
Metab. 96:3649–3660. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Beardwell CG, Adamson AR and Shalet SM:
Prolonged remission in florid Cushing’s syndrome following
metyrapone treatment. Clin Endocrinol (Oxf). 14:485–492. 1981.
|
|
8
|
Boscaro M, Sonino N, Rampazzo A and
Mantero F: Response of pituitary-adrenal axis to corticotrophin
releasing hormone in patients with Cushing’s disease before and
after ketoconazole treatment. Clin Endocrinol (Oxf). 27:461–467.
1987.
|
|
9
|
Sonino N, Boscaro M and Fallo F:
Pharmacologic management of Cushing syndrome: new targets for
therapy. Treat Endocrinol. 4:87–94. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Petersenn S, Schopohl J, Barkan A, et al:
Pasireotide (SOM230) demonstrates efficacy and safety in patients
with acromegaly: a randomized, multicenter, phase II trial. J Clin
Endocrinol Metab. 95:2781–2789. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bode H, Seiz M, Lammert A, et al: SOM230
(pasireotide) and temozolomide achieve sustained control of tumour
progression and ACTH secretion in pituitary carcinoma with
widespread metastases. Exp Clin Endocrinol Diabetes. 118:760–763.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Pivonello R, Ferone D, de Herder WW, et
al: Dopamine receptor expression and function in corticotroph
pituitary tumors. J Clin Endocrinol Metab. 89:2452–2462. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Mullan KR, Leslie H, McCance DR, Sheridan
B and Atkinson AB: The PPAR-gamma activator rosiglitazone fails to
lower plasma ACTH levels in patients with Nelson’s syndrome. Clin
Endocrinol (Oxf). 64:519–522. 2006.PubMed/NCBI
|
|
14
|
Pecori Giraldi F, Scaroni C, Arvat E, et
al: Effect of protracted treatment with rosiglitazone, a PPARgamma
agonist, in patients with Cushing’s disease. Clin Endocrinol (Oxf).
64:219–224. 2006.PubMed/NCBI
|
|
15
|
Liu J: Pharmacology of oleanolic acid and
ursolic acid. J Ethnopharmacol. 49:57–68. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sultana N and Ata A: Oleanolic acid and
related derivatives as medicinally important compounds. J Enzyme
Inhib Med Chem. 23:739–756. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sultana N: Clinically useful anticancer,
antitumor, and antiwrinkle agent, ursolic acid and related
derivatives as medicinally important natural product. J Enzyme
Inhib Med Chem. 26:616–642. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Liu J: Oleanolic acid and ursolic acid:
research perspectives. J Ethnopharmacol. 100:92–94. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kassi E, Papoutsi Z, Pratsinis H,
Aligiannis N, Manoussakis M and Moutsatsou P: Ursolic acid, a
naturally occurring triterpenoid, demonstrates anticancer activity
on human prostate cancer cells. J Cancer Res Clin Oncol.
133:493–500. 2007. View Article : Google Scholar
|
|
20
|
Shih WL, Yu FL, Chang CD, Liao MH, Wu HY
and Lin PY: Suppression of AMF/PGI-mediated tumorigenic activities
by ursolic acid in cultured hepatoma cells and in a mouse model.
Mol Carcinog. 52:800–812. 2013.PubMed/NCBI
|
|
21
|
Shyu MH, Kao TC and Yen GC: Oleanolic acid
and ursolic acid induce apoptosis in HuH7 human hepatocellular
carcinoma cells through a mitochondrial-dependent pathway and
downregulation of XIAP. J Agric Food Chem. 58:6110–6118. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Prasad S, Yadav VR, Sung B, et al: Ursolic
acid inhibits growth and metastasis of human colorectal cancer in
an orthotopic nude mouse model by targeting multiple cell signaling
pathways: Chemosensitization with capecitabine. Clin Cancer Res.
18:4942–4953. 2012. View Article : Google Scholar
|
|
23
|
Shan JZ, Xuan YY, Zheng S, Dong Q and
Zhang SZ: Ursolic acid inhibits proliferation and induces apoptosis
of HT-29 colon cancer cells by inhibiting the EGFR/MAPK pathway. J
Zhejiang Univ Sci B. 10:668–674. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Harmand PO, Duval R, Delage C and Simon A:
Ursolic acid induces apoptosis through mitochondrial intrinsic
pathway and caspase-3 activation in M4Beu melanoma cells. Int J
Cancer. 114:1–11. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
De Angel RE, Smith SM, Glickman RD,
Perkins SN and Hursting SD: Antitumor effects of ursolic acid in a
mouse model of postmenopausal breast cancer. Nutr Cancer.
62:1074–1086. 2010.PubMed/NCBI
|
|
26
|
Zheng QY, Jin FS, Yao C, Zhang T, Zhang GH
and Ai X: Ursolic acid-induced AMP-activated protein kinase (AMPK)
activation contributes to growth inhibition and apoptosis in human
bladder cancer T24 cells. Biochem Biophys Res Commun. 419:741–747.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhu W, Ou Y, Li Y, et al: A small-molecule
triptolide suppresses angiogenesis and invasion of human anaplastic
thyroid carcinoma cells via down-regulation of the nuclear
factor-kappa B pathway. Mol Pharmacol. 75:812–819. 2009. View Article : Google Scholar
|
|
28
|
Hollosy F, Meszaros G, Bokonyi G, et al:
Cytostatic, cytotoxic and protein tyrosine kinase inhibitory
activity of ursolic acid in A431 human tumor cells. Anticancer Res.
20:4563–4570. 2000.PubMed/NCBI
|
|
29
|
Gamby C, Waage MC, Allen RG and Baizer L:
Growth-associated protein-43 (GAP-43) facilitates peptide hormone
secretion in mouse anterior pituitary AtT-20 cells. J Biol Chem.
271:10023–10028. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
White A and Gibson S: ACTH precursors:
biological significance and clinical relevance. Clin Endocrinol
(Oxf). 48:251–255. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Chang L and Karin M: Mammalian MAP kinase
signalling cascades. Nature. 410:37–40. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Liu XS and Jiang J: Induction of apoptosis
and regulation of the MAPK pathway by ursolic acid in human
leukemia K562 cells. Planta Med. 73:1192–1194. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ruvolo PP, Deng X and May WS:
Phosphorylation of Bcl2 and regulation of apoptosis. Leukemia.
15:515–522. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Miyoshi N, Uchida K, Osawa T and Nakamura
Y: A link between benzyl isothiocyanate-induced cell cycle arrest
and apoptosis: involvement of mitogen-activated protein kinases in
the Bcl-2 phosphorylation. Cancer Res. 64:2134–2142. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Bonaccorsi I, Altieri F, Sciamanna I, et
al: Endogenous reverse transcriptase as a mediator of ursolic
acid’s anti-proliferative and differentiating effects in human
cancer cell lines. Cancer Lett. 263:130–139. 2008.PubMed/NCBI
|
|
36
|
Zhang YX, Kong CZ, Wang HQ, Wang LH, Xu CL
and Sun YH: Phosphorylation of Bcl-2 and activation of caspase-3
via the c-Jun N-terminal kinase pathway in ursolic acid-induced
DU145 cells apoptosis. Biochimie. 91:1173–1179. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zhang Y, Kong C, Zeng Y, et al: Ursolic
acid induces PC-3 cell apoptosis via activation of JNK and
inhibition of Akt pathways in vitro. Mol Carcinog. 49:374–385.
2010.PubMed/NCBI
|
|
38
|
Cha HJ, Bae SK, Lee HY, et al:
Anti-invasive activity of ursolic acid correlates with the reduced
expression of matrix metalloproteinase-9 (MMP-9) in HT1080 human
fibrosarcoma cells. Cancer Res. 56:2281–2284. 1996.PubMed/NCBI
|
|
39
|
Yang L, Liu X, Lu Z, et al: Ursolic acid
induces doxorubicin-resistant HepG2 cell death via the release of
apoptosis-inducing factor. Cancer Lett. 298:128–138. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Heaney AP, Fernando M, Yong WH and Melmed
S: Functional PPAR-gamma receptor is a novel therapeutic target for
ACTH-secreting pituitary adenomas. Nat Med. 8:1281–1287. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Schaaf C, Shan B, Buchfelder M, et al:
Curcumin acts as anti-tumorigenic and hormone-suppressive agent in
murine and human pituitary tumour cells in vitro and in vivo.
Endocr Relat Cancer. 16:1339–1350. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Green DR: Apoptotic pathways: paper wraps
stone blunts scissors. Cell. 102:1–4. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Nagata S: Apoptosis by death factor. Cell.
88:355–365. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Kroemer G and Reed JC: Mitochondrial
control of cell death. Nat Med. 6:513–519. 2000. View Article : Google Scholar
|
|
45
|
Kuwana T and Newmeyer DD: Bcl-2-family
proteins and the role of mitochondria in apoptosis. Curr Opin Cell
Biol. 15:691–699. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Achiwa Y, Hasegawa K and Udagawa Y:
Regulation of the phosphatidylinositol 3-kinase-Akt and the
mitogen-activated protein kinase pathways by ursolic acid in human
endometrial cancer cells. Biosci Biotechnol Biochem. 71:31–37.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Zhang YX, Kong CZ, Wang LH, et al: Ursolic
acid overcomes Bcl-2-mediated resistance to apoptosis in prostate
cancer cells involving activation of JNK-induced Bcl-2
phosphorylation and degradation. J Cell Biochem. 109:764–773.
2010.PubMed/NCBI
|
|
48
|
Cheng EH, Wei MC, Weiler S, et al: BCL-2,
BCL-X(L) sequester BH3 domain-only molecules preventing BAX- and
BAK-mediated mitochondrial apoptosis. Mol Cell. 8:705–711. 2001.
View Article : Google Scholar : PubMed/NCBI
|
